Triple-negative breast cancer (TNBC) is the most aggressive breast cancer subtype and is more likely to recur and to metastasize than other types of breast cancer. Five-year survival for patients with metastatic TNBC is estimated to be 15%, which emphasizes the unmet clinical need for novel first-line therapies in this space. Clinical trial data presented…

Moving away from the CLEOPATRA regimen for first-line treatment of all patients with HER2+ metastatic breast cancer has taken over a decade, but recent clinical trials in this space highlight new potential approaches to induction and maintenance therapy for select patients. Additionally, real-world treatment may soon be tailored by hormone receptor status and presence of…

Many patients with HR+/HER2- breast cancer develop resistance to endocrine therapy, making management of metastatic disease complicated. Alterations in the PI3K/AKT/mTOR pathway are often the cause of this resistance, making testing for related alterations vital for metastatic therapeutic selection. Once a patient is a candidate for PI3K or AKT inhibition, breast cancer care providers must…

Metastatic triple-negative breast cancer (mTNBC) is a highly symptomatic disease that is associated with poor survival outcomes so new approaches to first-line therapies have been desperately needed. Although both antibody–drug conjugates that made waves at the podiums of large oncology meetings in 2025 including the San Antonio Breast Cancer Symposium, reported positive data based on…

Immunotherapy, PARP inhibitors, and antibody-drug conjugates have revolutionized the therapeutic landscape for triple-negative breast cancer (TNBC). With new compounds and combinations under investigation, lessons learned in metastatic TNBC are becoming equally valuable in early-stage disease, as well as in other subsets of breast cancer. Learn from Sonya Reid, MD, MPH, and Manali Bhave, MD, about…